SCHEMBL680257

SCHEMBL680257

CN/N=C/c1cc(Oc2ccc([N+](=O)[O-])cc2F)c(Br)cc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 4/20 0.44
MAPT P10636 7/20 0.42
ALDH1A1 P00352 6/20 0.39
MAPK1 P28482 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 3/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GAA P10253 2/20 0.37
CYP2D6 P10635 1/20 0.37
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
S1PR4 O95977 1/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 1/20 0.36
POLB P06746 2/20 0.35
LIG1 P18858 2/20 0.35
LIG3 P49916 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680258 1.00 HSPB1 (0.44) HSPB1MAPTALDH1A1MAPK1L3MBTL1
SCHEMBL23629494 0.89 HSPB1 (0.41) HSPB1MAPTALDH1A1MAPK1L3MBTL1
SCHEMBL680402 0.83 HSPB1 (0.50) HSPB1MAPTALDH1A1MAPK1L3MBTL1
SCHEMBL23081424 0.78 HSPB1 (0.44) HSPB1MAPTALDH1A1MAPK1L3MBTL1
SCHEMBL21887154 0.74 ALDH1A1 (0.47) MAPTALDH1A1MAPK1L3MBTL1KMT2A
SCHEMBL28536419 0.74 MAPT (0.36) MAPTALDH1A1MAPK1L3MBTL1KMT2A
SCHEMBL23160924 0.74 MAPT (0.36) MAPTALDH1A1MAPK1L3MBTL1KMT2A
SCHEMBL29902520 0.74 MAPT (0.36) MAPTALDH1A1MAPK1L3MBTL1KMT2A
SCHEMBL29845685 0.71 HSPB1 (0.53) HSPB1MAPTALDH1A1MAPK1L3MBTL1
SCHEMBL20154998 0.71 HSPB1 (0.53) HSPB1MAPTALDH1A1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC HSPB1 1726/4885MAPT 4502/4885ALDH1A1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.